耐多药肺结核患者治疗结果及其影响因素调查  

Treatment outcomes and their impact factors of multidrug-resistant tuberculosis patients

作　　者：李卫彬 马丽萍[2] 李新旭[3] 刘占峰[2] 马振亚 屈亚虹 

机构地区：[1]开封市结核病防治所,河南开封475004 [2]河南省疾病预防控制中心结防所,河南郑州450016 [3]中国疾病预防控制中心结核病预防控制中心,北京102206

出　　处：《临床肺科杂志》2012年第10期1831-1834,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的了解耐多药肺结核患者的治疗结果及其影响因素。方法对纳入项目治疗的患者进行问卷调查,并将相关结果进行病例对照研究。结果 70例接受耐多药治疗的患者中,32例治愈,1例完成疗程;多因素logistic回归分析,年龄>38岁和耐多药治疗前累计服药>15个月是患者未治愈的主要危险因素。结论规范二线药物使用,前移耐多药检测关口和加强患者的治疗管理,对具有治疗失败高风险患者进行个体化调整。Objective To identify the treatment outcomes and their factors impacting on treatment failure of muhidrug-resistant tuberculosis （MDR-TB） patients, and provide the scientific data for the treatment of MDR-TB. Methods The MDR-TB patients received the questionnaire interviews before MDR-TB treatment, and the case-control study according to the treatment outcomes （cure or not） was not conducted until all the MDR-TB patients completed the whole course of MDR-TB treatment in July 2011. Results Of 70 MDR-TB pa- tients totally receiving MDR- TB treatment, 32 （45.71%） were cured, 1 （1.43%） completed treatment, etc; Multiple logistic regres- sions demonstrated that more than 38 years old and more than 15 months of cumulative time of taking anti-TB drugs before MDR-TB treat- mentwere significantly associated with treatment failure of MDR-TB. Conclusion To further improve the treatment effects of MDR-TB, the use of second-line drugs among TB patients should be regulated, the checkpoints of MDR-TB be advanced, the treatment management of MDR-TB patients be strengthened, and the standardized treatment regimens be adjusted individualizedly for MDR-TB patients with high risk of treatment failure.

关 键 词：结核 肺/预防控制 耐多药 治疗结果 影响因素 

分 类 号：R521[医药卫生—内科学]